GLP1R and hyperinsulinemic hypoglycemia: In addition, some researchers have attributed post-RYGB hyperinsulinemic hypoglycemia to GLP-1-mediated expansion of β-cell mass (nesidioblastosis) (77, 78), with reversal of the symptoms after blockade of GLP-1 receptor with exendin 9–39 (79).